.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Express Scripts
Farmers Insurance
Teva
McKinsey
Fuji
Johnson and Johnson
Julphar
Medtronic
Mallinckrodt

Generated: July 28, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,160,559 protect, and when does it expire?


Patent ► Subscribe protects RAZADYNE ER and is included in one NDA. There have been two Paragraph IV challenges on Razadyne ER.

This patent has forty-two patent family members in thirty-five countries.

Summary for Patent: ► Subscribe

Title:Controlled release galantamine composition
Abstract:The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.
Inventor(s): McGee; John Paul (Antwerp, BE), Gilis; Paul Marie Victor (Beerse, BE), De Weer; Marc Maurice Germain (Vosselaar, BE), de Conde; Valentin Florent Victor (Lommel, BE), de Bruijn; Herman Johannes Catherina (Meer, BE), Van Dycke; Frederic Anne Rodolf (Antwerp, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:09/868,991
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device; Process; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-001Apr 1, 2005ABRXYesYes► Subscribe► SubscribeY
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-002Apr 1, 2005ABRXYesNo► Subscribe► SubscribeY
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-003Apr 1, 2005ABRXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98204447Dec 24, 1998
PCT Information
PCT FiledDecember 20, 1999PCT Application Number:PCT/EP99/10257
PCT Publication Date:July 06, 2000PCT Publication Number: WO00/38686

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)1414► Subscribe
African Regional IP Organization (ARIPO)200102219► Subscribe
Argentina022008► Subscribe
Argentina066313► Subscribe
Austria252386► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Baxter
Merck
Daiichi Sankyo
Cantor Fitzgerald
Healthtrust
Teva
UBS
Deloitte
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot